CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 389 enrolled
Drug / intervention
Magnesium +1 moredrug
Likely dose
Magnesium 100 mg/kgAI-extracted
Key inclusion· 1
  • ✓Coronary heart disease
Key exclusion· 2
  • ✕Early dementia
  • ✕History of psychiatric illness

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00041392
NCT00041392Phase 2Completed
CompareCT.gov

PeriOperative Interventional Neuroprotection Trial (POINT)

Duke University·interventional·Posted Jul 9, 2002·Updated Jul 30, 2013

In Brief

A Phase 2 clinical trial evaluating Magnesium and 0.9% saline for Coronary Disease and 3 related conditions. Completed, enrolled 389 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the effects of supplemental magnesium on the neurocognitive function of individuals undergoing coronary artery bypass graft (CABG) surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease, Heart Diseases, Cardiovascular Diseases, Neurologic Manifestations
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 9, 2002
Enrollment StartDec 1, 2001
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 24.0 years ago

Interventions

Magnesiumdrug

100 mg/kg

0.9% salinedrug

Placebo